Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Acadia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here […]

Pomerantz LLP announces that a securities fraud class action lawsuit has been filed against Sina Corporation (“Sina” or the “Company”)(formerly NASDAQ: SINA) and certain of its executive officers (collectively, “Defendants”)on behalf of investors who sold Sina ordinary shares, including those that sold into the Merger (defined below), between October 13, 2020 and March 22, 2021,

Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”)(NYSE: KBR). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg

Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”)(NYSE: NX). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares

Pomerantz LLP is investigating claims on behalf of investors of Coherent Corp. (“Coherent” or the “Company”) (NYSE: COHR).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Coherent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether CarMax and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Brunello Cucinelli S.p.A. (“Brunello Cucinelli” or the “Company”) (OTCMKTS: BCUCY).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Brunello Cucinelli and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Pomerantz LLP is investigating claims on behalf of investors of Braskem S.A. (“Braskem” or the “Company”) (NYSE: BAK).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Braskem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. (“Axogen” or the “Company”) (NASDAQ: AXGN).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Axogen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. (“Avita” or the “Company”) (NASDAQ: RCEL).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Avita and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here